Epic Sciences to Present New Data Demonstrating Expanded Clinical Utility of Circulating Tumor Cell (CTC) Count at 2021 ASCO Genitourinary (GU) Cancers Symposium

 

Validation of CTC count as a prognostic biomarker in men starting 2nd generation AR-targeted agents

Pre-planned analysis of CTC count in the phase IV CARD trial as a prognostic and response-to-therapy biomarker

SAN DIEGO--(BUSINESS WIRE)-- Epic Sciences, Inc. announced today it will present two abstracts at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium virtual meeting on February 11 - 13, 2021. The abstracts feature analysis on the prognostic and predictive value of CTC enumeration in men with progressing mCRPC starting a standard-of-care therapy.

The first abstract presents data on CTC enumeration prior to treatment. "The primary focus of this analysis was to clinically validate CTC number, defined as any cytokeratin positive CD45 negative epithelial cell, enumerated on the Epic Sciences platform, as a prognostic biomarker in men with progressing mCRPC being treated with abiraterone or enzalutamide. Further, we also observed that, using this base definition, CTC count showed strong correlation and comparable associations with overall survival and progression free survival to counts determined using the FDA-cleared CellSearch® predicate device in time-matched samples," said Howard Scher, MD FASCO at Memorial Sloan Kettering Cancer Center.

The second abstract presents the pre-planned CTC biomarker analysis portion of the phase IV CARD trial which randomized cabazitaxel versus AR-signaling inhibitors in 3rd line mCRPC patients. Professor Johann de Bono at The Institute of Cancer Research, London and lead author of the study commented, "We observed that CTC counts pre-treatment were independently prognostic and that patients who maintained low counts at 3-weeks on-therapy had longer survival and a higher rate of RECIST response."

Epic has demonstrated its expertise in the development of blood-based biopsies that predict therapy response with the launch of the Oncotype DX AR-V7 Nucleus Detect® test, commercially available and reimbursed by Medicare. That test assists physicians in choosing between androgen-receptor-directed therapies and taxane chemotherapy and is offered in the U.S. through Exact Sciences.

Following are the details for the two poster sessions:

Title: Development and validation of circulating tumor cells (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
First Author: Howard Scher, MD
Date: Thursday, February 11, 2021
Poster Session: Prostate Cancer - Advanced Disease
Abstract: 157

Title: CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial
First Author: Johann de Bono, MD, PhD
Date: Thursday, February 11, 2021
Poster Session: Prostate Cancer - Advanced Disease
Abstract: 161

About Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to guide therapy selection and monitor disease progression thereby personalizing and advancing the treatment and management of prostate and breast cancer. The company's approach, Comprehensive Cancer Profiling, leverages proven and proprietary CTC capabilities, and adds ctDNA and immune cell analysis, to provide more complete data allowing more efficient analysis and clearer insights. The company's CTC-based diagnostic test, Oncotype DX AR-V7 Nucleus Detect® test, is the first and only Medicare reimbursed liquid biopsy for metastatic prostate cancer and is available to oncologists and urologists from Exact Sciences. Today Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes by providing clinicians with efficient information to guide treatment plans. Epic Sciences is headquartered in San Diego. Further information is available on the company's website, www.epicsciences.com. Stay in touch on LinkedIn, Facebook, or on Twitter@EpicSciences.

"The Power of Clarity" is a registered trademark, and the stylized "e" and "Comprehensive Cancer Profiling" are trademarks of Epic Sciences, Inc. CellSearch® is a registered trademark of Menarini Silicon Biosystems, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005314/en/

 

Media Contacts:
CG Life - Bill Rader
brader@cglife.com

 

Source: Epic Sciences, Inc.

 

View this news release online at:
http://www.businesswire.com/news/home/20210211005314/en

Did you like this article?